The financing round was led by Archangel Investors to support ongoing Phase IIa trials for its lead antibiotic.
"There remains a desperate need for novel treatments in our armoury to treat C. difficile infections. The work that MGB Biopharma is undertaking is both important and innovative and the results that have been achieved so far have been very encouraging."
